Navitoclax is an investigational small molecule that functions as a BCL-2 family inhibitor. It is designed to induce apoptosis, or programmed cell death, by inhibiting BCL-2, BCL-XL, and BCL-W proteins, which are critical for cancer cell survival. These proteins are often overexpressed in various cancers, helping cancer cells evade the natural cell death process.
